4.4 Article

Role of new agents in the treatment of colorectal cancer

Journal

SURGICAL ONCOLOGY-OXFORD
Volume 13, Issue 2-3, Pages 75-81

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.suronc.2004.09.004

Keywords

colorectal cancer; chemotherapy; irinotecan; oxaliplatin; capecitabine; UFT; cetuximab

Ask authors/readers for more resources

5-Fluorouracil has been the basis of chemotherapy for colorectal cancer over the past 40 years. Various methods of administration of this drug have been investigated to identify the most efficacious form of administration. Two other agents in common usage are Irinotecan and Oxaliplatin. Both of these are being studied to determine their role as primary or second line agents and their efficacy in combination with each other and 5-FU. New agents undergoing development include COX2 inhibitors and epidermal growth factor receptor inhibitor targeting drugs i.e. Cetuximab, Tyrosine kinase inhibitors and Vascular endothelial growth factor receptor inhibitors. This article reviews the above mentioned drugs and includes a recommended approach to chemotherapy in metastatic colorectal cancer. (C) 2004 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available